The interleukin-1 receptor antagonist gene and the inhibitor of kappa B-like protein gene polymorphisms are not associated with myocardial infarction in Slovene population with type 2 diabetes

被引:0
作者
Kariz, Stojan
Milutinovic, Aleksandra
Bregar, Dejan
Terzic, Ibrahim
Terzic, Rifet
Lovrecic, Luca
Herova, Magdalena
Hruskovicova, Helena
Peterlin, Borut
Petrovic, Danijel
Zorc-Pleskovic, Ruda
机构
[1] Univ Ljubljana, Fac Med, Inst Histol & Embryol, Ljubljana 1000, Slovenia
[2] Gen Hosp Izola, Dept Internal Med, Izola, Slovenia
[3] Univ Clin Cardovasc Dis Tuzla, Tuzla, Bosnia & Herceg
[4] Sch Med, Dept Biol & Human Genet, Tuzla, Bosnia & Herceg
[5] Univ Med Ctr Ljubljana, Div Med Genet, Dept Obstet & Gynecol, Ljubljana, Slovenia
关键词
interleukin-1 receptor antagonist polymorphism; inhibitor of kappa B-like protein gene polymorphism; myocardial infarction; type; 2; diabetes;
D O I
暂无
中图分类号
Q98 [人类学];
学科分类号
030303 ;
摘要
In this study we investigated the association of the interleukin-1 receptor antagonist gene variable number tandem repeat (IL1RN VNTR)polymorphism and of the inhibitor of kappa B-likeprotein (IKBL) gene polymorphism with myocardial infarction (MI) in a group of patients with type 2 diabetes. The IL1RN VNTR and the IKBL + 738T > C gene polymorphisms were tested in 374 Caucasians: 151 cases with MI and 223 subjects with no history of coronary artery disease. The 1L1RN VNTR polymorphism was not a risk factor for MI in Caucasians with type 2 diabetes (genotype 22 vs. the rest: odds ratio (OR) 1. 6; 95% confidence interval (CI) = 0. 8-3.5; p = 0.2). We also failed to demonstrate that IKBL + 738T > C gene polymorphism was associated with MI in patients with type 2 diabetes (OR =0.9; 95% CI = 0.3-2.6; p=0.9). We provide evidence that the IL1RN VNTR and the IKBL + 738T > C gene polymorphisms are not risk factors for MI in Caucasians with type 2 diabetes.
引用
收藏
页码:503 / 507
页数:5
相关论文
共 38 条
[1]   CHARACTERIZATION OF A NOVEL GENE IN THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX THAT ENCODES A POTENTIAL NEW MEMBER OF THE I-KAPPA-B FAMILY OF PROTEINS [J].
ALBERTELLA, MR ;
CAMPBELL, RD .
HUMAN MOLECULAR GENETICS, 1994, 3 (05) :793-799
[2]   Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies [J].
Andreotti, F ;
Porto, I ;
Crea, F ;
Maseri, A .
HEART, 2002, 87 (02) :107-112
[3]   Imbalance of the interleukin 1 system in colonic mucosa - association with intestinal inflammation and interleukin 1 receptor agonist genotype 2 [J].
Andus, T ;
Daig, R ;
Vogl, D ;
Aschenbrenner, E ;
Lock, G ;
Hollerbach, S ;
Kollinger, M ;
Scholmerich, J ;
Gross, V .
GUT, 1997, 41 (05) :651-657
[4]   Screening for silent myocardial ischaemia in type 2 diabetic patients with additional atherogenic risk factors: applicability and accuracy of the exercise stress test [J].
Bacci, S ;
Villella, M ;
Villella, A ;
Langialonga, T ;
Grilli, M ;
Rauseo, A ;
Mastroianno, S ;
De Cosmo, S ;
Fanelli, R ;
Trischitta, V .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 147 (05) :649-654
[5]   Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[6]   Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events [J].
Biasucci, LM ;
Liuzzo, G ;
Fantuzzi, G ;
Caligiuri, G ;
Rebuzzi, AG ;
Ginnetti, F ;
Dinarello, CA ;
Maseri, A .
CIRCULATION, 1999, 99 (16) :2079-2084
[7]   Diabetes-associated sustained activation of the transcription factor nuclear factor-κB [J].
Bierhaus, A ;
Schiekofer, S ;
Schwaninger, M ;
Andrassy, M ;
Humpert, PM ;
Chen, J ;
Hong, M ;
Luther, T ;
Henle, T ;
Klöting, I ;
Morcos, M ;
Hofmann, M ;
Tritschler, H ;
Weigle, B ;
Kasper, M ;
Smith, M ;
Perry, G ;
Schmidt, AM ;
Stern, DM ;
Häring, HU ;
Schleicher, E ;
Nawroth, PP .
DIABETES, 2001, 50 (12) :2792-2808
[8]   Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion [J].
Brand, K ;
Page, S ;
Rogler, G ;
Bartsch, A ;
Brandl, R ;
Knuechel, R ;
Page, M ;
Kaltschmidt, C ;
Baeuerle, PA ;
Neumeier, D .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (07) :1715-1722
[9]  
BYRNE CE, 2004, BMC MED GENET, V1, P5
[10]  
CHOMARAT P, 1995, J IMMUNOL, V154, P1432